StockNews.AI
SANA
StockNews.AI
141 days

The Gross Law Firm Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SANA

1. Sana is facing allegations of misleading shareholders about financial risks. 2. Claims include insufficient funds to sustain operations and advance product candidates. 3. The firm may decrease funding and reduce headcount to preserve cash. 4. Shareholders are encouraged to register for a class action lawsuit. 5. Deadlines for participating in the lawsuit are set for May 20, 2025.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The allegations of misleading financial statements can severely impact investor confidence, akin to cases like Valeant Pharmaceuticals' scrutiny over financial practices, which led to significant stock declines.

How important is it?

The potential legal fallout and financial implications could lead to substantial investor losses and market volatility, making this event highly relevant to SANA's stock performance.

Why Short Term?

The immediacy of the class-action announcement will likely trigger a rapid market reaction, reflecting recent investor responses to similar legal challenges faced by biotech firms.

Related Companies

NEW YORK, March 31, 2025 /PRNewswire/ --

The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).

Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=139423&from=4

CLASS PERIOD:

March 17, 2023 to November 4, 2024

ALLEGATIONS:

The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (ii) SC291 in oncology, SC379, and SG299 were less promising than defendants had led investors to believe; (iii) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (iv) accordingly, defendants overstated Sana's financial capacity to maintain its current operations and advance its existing product candidates; and (v) as a result, defendants' public statements were materially false and/or misleading at all relevant times.

DEADLINE:

May 20, 2025. Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=139423&from=4

NEXT STEPS FOR SHAREHOLDERS:

Once you register as a shareholder who purchased shares of SANA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is May 20, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM?

The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: contact@grosslawfirm.com
Phone: (646) 453-8903

SOURCE: The Gross Law Firm

Related News